Immunovant, Inc. (IMVT)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $8.15B
- P/E ratio
- —
- EPS
- —
- Volume
- 721,492
- 52-week high
- —
- 52-week low
- —
- Open
- $40.21
- Day high
- $41.21
- Day low
- $39.77
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2026 | — | -$505.61M | -$2.77 |
| 2025 | — | -$413.84M | -$2.73 |
| 2024 | — | -$259.34M | -$1.88 |
| 2023 | — | -$210.96M | -$1.71 |
| 2022 | — | -$156.73M | -$1.43 |
About Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
- CEO
- Eric Venker
- Employees
- 362
- Country
- US
- IPO date
- Jun 21, 2019
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Immunovant, Inc.'s stock price today?
- IMVT is trading at $39.92 as of Jul 20, 2026.
- What is Immunovant, Inc.'s market cap?
- Immunovant, Inc. (IMVT) has a market capitalization of $8.15B.
- Does Immunovant, Inc. pay a dividend?
- Immunovant, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Immunovant, Inc. in?
- Immunovant, Inc. operates in the Healthcare sector.